Reinforcing subjective effects of (±) 3,4-methylenedioxymethamphetamine (“ecstasy”) may be separable from its neurotoxic actions: Clinical evidence

Research output: Contribution to journalArticlepeer-review

Abstract

(±)3,4-Methylenedioxymethamphetamine (MDMA), a synthetic amphetamine derivative used recreationally by humans, damages brain serotonin neurons in experimental animals. In preclinical studies, serotonin reuptake inhibitors block MDMA-induced serotonin release; they also block MDMA neurotoxicity. Whether serotonin reuptake inhibitors also block MDMA’s psychoactive effects in humans has not been established. Reported herein are four individuals who describe their experiences after ingesting fluoxetine, a potent and selective serotonin reuptake inhibitor, before MDMA ingestion. Their reports indicate that fluoxetine does not block MDMA’s reinforcing subjective effects and raise the possibility that MDMA’s psychoactive effects may be separable from its neurotoxic actions.

Original languageEnglish (US)
Pages (from-to)214-217
Number of pages4
JournalJournal of clinical psychopharmacology
Volume13
Issue number3
StatePublished - Jun 1993

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Reinforcing subjective effects of (±) 3,4-methylenedioxymethamphetamine (“ecstasy”) may be separable from its neurotoxic actions: Clinical evidence'. Together they form a unique fingerprint.

Cite this